Pathology and Lab Medicine - Global Oncology Academy

1-16 of 36

Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
COVID-19: On The Frontlines
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Hallie Blevins, PhD; Marlene Mimi Maeusli, PhD.
- Hallie Blevins, PhD
- Marlene Mimi Maeusli, PhD.
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CE
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE; Samir Dalia, MD
0.25 credits
- Joseph Kim, MD, MPH, MBA, FACHE
- Samir Dalia, MD
- Christopher Jurief
0.25 credits
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Clinician's Roundtable
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Ashley Baker, MSN, PMHNP; Heather Allen, PhD
- Ashley Baker, MSN, PMHNP
- Heather Allen, PhD
- Ran Li, PhD
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
Project Oncology®
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
Matt Birnholz, MD
- Matt Birnholz, MD
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Project Oncology®
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Charles Turck, PharmD, BCPS, BCCCP; Martin Dietrich, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Martin Dietrich, MD, PhD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALL
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Ryan Quigley; Amanda Winters, MD, PhD
- Ryan Quigley
- Amanda Winters, MD, PhD
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Project Oncology®
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Ryan Quigley; Hallie Blevins, PhD
- Ryan Quigley
- Hallie Blevins, PhD
- Marlene Mimi Maeusli, PhD.
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Balazs Halmos, MD, MS
- Balazs Halmos, MD, MS
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Balazs Halmos, MD, MS
- Balazs Halmos, MD, MS
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
Junaid Arshad, MD, MS
- Junaid Arshad, MD, MS
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Junaid Arshad, MD, MS
- Junaid Arshad, MD, MS
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
1.25 program credits
- Ignacio Duran, MD
1.25 program credits
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD; Wenxin Xu, MD
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits

Prev
1
2
3
Next

1/3